Risk of Sprint Fidelis defibrillator lead failure is highly dependent on age  by Girerd, Nicolas et al.
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Summary
Background.  —  In  2007,  Medtronic  Sprint  Fidelis  deﬁbrillator  leads  were  taken  off  the  market
due to  a  high  rate  of  lead  failure.  Current  data  do  not  allow  for  risk  stratiﬁcation  of  patients
with regard  to  lead  failure.
Aims.  —  We  sought  to  determine  predictors  of  Sprint  Fidelis  lead  failure.
Methods.  —  Between  2004  and  2007,  269  Sprint  Fidelis  leads  were  implanted  in  258  patients  in
our centre.  Variables  associated  with  lead  failure  were  assessed  by  the  Kaplan-Meier  method
and a  Cox  survival  model.
Results.  —  During  a  median  follow-up  of  2.80  years  (maximum  5.32),  we  observed  33  (12.3%)
Sprint Fidelis  lead  failures  (5-year  survival,  65.6%  ±  7.5%).  In  univariate  analysis,  age  was  the
only predictor  of  lead  failure  (hazard  ratio  [HR]  for  1-year  increase  0.97;  95%  conﬁdence  interval
[CI] 0.95—0.99;  p  =  0.009).  Patients  aged  <  62.5  years  (median)  had  a  signiﬁcantly  increased  risk
of lead  failure  compared  with  patients  aged  >  62.5  years  (HR  2.80;  CI  1.30—6.02;  p  =  0.009).  Sur-
vival without  Sprint  Fidelis  lead  failure  was  55.6%  ±  10.4%)  in  patients  aged  <  62.5  years  (24/134
leads) vs  78.6%  ±  8.8%  in  patients  aged  >  62.5  years  (9/135  leads).  The  annual  incidence  of  lead
failure in  patients  aged  <  62.5  years  was  11.6%  ±  4.9%  during  the  fourth  year  after  implantation
and 22.9%  ±  13.2%  during  the  ﬁfth  year.
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; ICD, implantable cardioverter deﬁbrillator.
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Conclusion.  —  Overall,  we  found  a  higher  rate  of  Sprint  Fidelis  lead  dysfunction  than  previously
described.  Lead  failure  was  much  more  frequent  in  younger  patients.  Our  results  emphasize  the
need for  close  follow-up  of  younger  patients  with  Sprint  Fidelis  leads  and  suggest  that,  in  these
patients, the  implantation  of  a  new  implantable  cardioverter  deﬁbrillator  lead  at  the  time  of
generator replacement  might  be  reasonable.
© 2011  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Rationnel.  —  Les  sondes  de  déﬁbrillation  Sprint  Fidelis  ont  été  retirées  du  marché  en  2007  en
raison d’un  risque  accru  de  dysfonction.  L’état  actuel  des  connaissances  ne  permet  pas  une
stratiﬁcation  du  risque  des  patients  porteurs  de  sondes  Sprint  Fidelis.
Objectif.  —  Identiﬁer  les  prédicteurs  de  dysfonction  de  sonde  Sprint  Fidelis.
Méthodes.  — Deux  cent  soixante-neuf  sondes  ont  été  implantées  chez  258  patients  dans  notre
centre entre  2004  et  2007.  Les  facteurs  prédictifs  de  rupture  de  sonde  ont  été  étudiés  grâce  à
des modèles  de  Cox.
Résultats.  —  Au  cours  des  2,80  années  de  suivi  médian  (maximum  5,32),  33  ruptures  (12,3  %)
de sondes  ont  été  identiﬁées  (65,6  %  ±  7,5  %  de  survie  à  cinq  ans),  En  analyse  univariée,  seul
l’âge est  associé  au  risque  de  dysfonction  de  sonde  (hazard  ratio  [HR]  pour  un  an,  0,97  ;  inter-
valle de  conﬁance  à  95  %  [IC],  0,95—0,99  ;  p  =  0,009).  Les  patients  âgés  de  moins  de  62,5  ans  à
l’implantation  comparés  aux  patients  âgés  de  plus  de  62,5  ans  (médiane  de  la  cohorte)  ont  un
risque signiﬁcativement  supérieur  de  dysfonction  de  sonde  (HR,  2,80  ;  CI,  1,30—6,02  ;  p  =  0,009).
La survie  sans  dysfonction  de  sonde  est  de  55,6  %  ±  10,4  %  pour  les  patients  de  moins  de  62,5  ans
(24/134  sondes),  contre  78,6  %  ±  8,8  %  chez  ceux  de  plus  de  62,5  ans  (9/135  sondes).  L’incidence
annuelle  de  rupture  chez  les  patients  de  moins  de  62,5  ans  est  de  11,6  %  ±  4,9  %  au  cours  de  la
quatrième  année  postimplantation  et  de  22,9  %  ±  13,2  %  au  cours  de  la  cinquième  année.
Conclusion.  —  Dans  notre  cohorte,  le  risque  de  dysfonction  de  sonde  Sprint  Fidelis  apparaît  plus
important que  rapporté  précédemment.  Le  risque  de  dysfonction  de  sonde  est  particulièrement
important  chez  les  patients  jeunes.  Nos  résultats  suggèrent  que  l’implantation  d’une  nouvelle
sonde de  déﬁbrillation  lors  du  changement  de  boîtier  est  une  option  raisonnable.
 Tou
r
c
[
m
f
u
s
n
w
f
p
a
t
f
M
S
B© 2011  Elsevier  Masson  SAS.
Introduction
ICDs  increase  survival  in  patients  at  high  risk  of  sudden
cardiac  death  [1—4]. ICD  leads  have  been  called  the  ‘weak-
est  link’  of  the  ICD  systems  [5,6]. Indeed,  8  years  after
implantation,  ICD  lead  survival  is  reportedly  as  low  as  60%
[7].
Medtronic  Sprint  Fidelis  deﬁbrillator  leads  (Medtronic,
Inc.,  Minneapolis,  MN,  USA)  were  removed  from  the  mar-
ket  in  October  2007  because  of  a  high  rate  of  lead  failure.
An  increased  risk  of  failure  of  Sprint  Fidelis  leads  was
reported  only  a  few  months  earlier  by  Hauser  et  al.  [8].
Such  lead  failure  may  result  in  painful,  inappropriate  ICD
shocks,  failure  to  deliver  life-saving  therapy  and,  rarely,
death  [9,10].
With  268,000  leads  implanted  worldwide,  correct  identi-
ﬁcation  of  patients  who  will  develop  lead  failure  is  essential.
This  need  is  ampliﬁed  by  the  fact  that  the  patients  with
Sprint  Fidelis  leads  were  implanted  between  2004  (market
launch  in  USA)  and  2007  (worldwide  withdrawal),  and  will
most  likely  undergo  deﬁbrillator  generator  replacement  in
the  next  3  years.  It  would  be  optimal  to  identify  patients  at
high  risk  of  Sprint  Fidelis  lead  failure  in  order  to  implant  a
prophylactic  alternative  ICD  lead,  with  or  without  removal
of  the  Sprint  Fidelis  lead,  at  the  time  of  the  generator
replacement.  Reoperation  for  lead  replacement  soon  after
generator  replacement  would  expose  patients  to  a  higher
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isk  of  procedural  complications  [11,12]  and,  more  speciﬁ-
ally,  might  expose  them  to  an  increased  risk  of  infections
11]. Consequently,  it  would  be  of  great  interest  to  deter-
ine  the  clinical  proﬁle  of  patients  at  high  risk  of  lead
ailure.
The  risk  factors  for  Sprint  Fidelis  lead  failure  are  poorly
nderstood.  Younger  age  at  implantation  [13—16], female
ex  [14], greater  left  ventricular  ejection  fraction  [17]  and
oncephalic  venous  access  [17]  are  reportedly  associated
ith  greater  risk.  However,  studies  evaluating  risk  factors
or  Sprint  Fidelis  lead  dysfunction  often  had  low  statistical
ower  and  reported  conﬂicting  results.  Current  data  do  not
llow  risk  stratiﬁcation  of  patients  with  Sprint  Fidelis  leads.
We  sought  to  identify  demographic  and  implant
echnique-related  factors  predisposing  to  Sprint  Fidelis  lead
ailure.
ethods
tudy population
etween  2004  and  2007,  258  patients  aged  17  years  or  older
eceived  a  Sprint  Fidelis  lead  in  our  centre.  As  11  patients
ith  explanted  Sprint  Fidelis  leads  were  also  implanted  with
 Sprint  Fidelis  lead  during  the  second  procedure,  in  total
e  analysed  269  Sprint  Fidelis  leads.
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Patients  implanted  with  Sprint  Fidelis  leads  were  mostly
men  (86.6%)  and  most  had  nonischaemic  heart  failure.  The
majority  of  patients  had  an  ejection  fraction  <  35%  and
received  model  6931  leads  (Table  1).
Table  1 Baseline  characteristics  of  the  population.
Clinical  characteristics  Whole  cohort
(n  =  269)
Age  (years) 60.6  ±  13.7
Female  sex 13.4
Underlying  cardiomyopathy
Nonischaemic  heart  failure
(dilated,  valvular  or
congenital)
56.6
Ischaemic  heart  failure  34.5
Others  (Brugada  syndrome,
hypertrophic  cardiomyopathy,
etc.)
9.0
Left  ventricular  ejection  fraction
(%)
31.6 ±  13.0
Implanted  ICD  systems
Single-chamber  device 48.5
Dual-chamber  device  14.2
Biventricular  device 2.6
Triple-chamber  device 24.8
Lead  model
6930  0.8
6931  78.0
6948  0.4
6949  20.8
Implantation  technique
Device  side
Right  8.4
Left  91.6
Venous  access
Cephalic  cut-down  59.3
Subclavian  access  40.7
Lead  tip  position
Apex  57.2
Septum  42.8
Lead  variables  at  implantation
Impedance  (ohms)  730.1  ±  203.8
Detection  threshold  (mV)  12.1  ±  5.6
Pacing  threshold  (V)  0.75  ±  0.33
Follow-up  data
Median  (interquartile  range)
follow-up  (years)
2.80  ±  2.29
Lead  failure,  n 33
Deaths,  n 37
Cardiac  transplantation,  n 18
Lead  extraction  without  lead
failure,  n
1390  
mplantation techniques
eads  were  inserted  preferably  via  left-sided  venous  access
y  cephalic  cut-down  or,  alternatively,  from  the  subclavian
ein  using  (most  commonly)  standard  puncture  and  intro-
ucer  sheath  techniques.  The  axillary  approach  was  never
sed.  Depending  on  the  implanter’s  preference,  leads  were
laced  in  an  apex  or  septum  position.  Pacing  threshold  and
ensing  measurements  were  obtained  at  the  time  of  the  pro-
edure  in  every  patient.  The  general  policy  of  our  institution
t  the  time  of  the  study  was  to  verify  adequate  detection
nd  termination  of  ventricular  ﬁbrillation.  When  needed,
trial  and  left  ventricular  pacing  leads  were  added.
ata collection
he  preoperative  and  implantation  data  for  all  patients
ndergoing  Sprint  Fidelis  lead  implantation  at  our  institution
ere  retrospectively  collected  and  entered  into  a  comput-
rized  database.  Demographic  and  clinical  data,  as  well  as
spects  of  the  implantation  technique,  including  side  of  ICD
mplant  and  type  of  venous  access,  were  obtained  through
eview  of  medical  records.  All  patients  implanted  in  our
entre  were  recorded  and  followed  up.
All  cases  in  which  the  lead  was  capped  or  removed  were
eviewed  to  determine  whether  removal  of  the  lead  from  the
CD  system  was  due  to  lead  fracture.  Circumstances  of  each
ractured  lead  were  reviewed.  Clinical  presentation  and  ICD
nterrogation  variables  at  the  time  of  the  lead  fracture  were
ollected.
ead fracture deﬁnition
 lead  was  considered  fractured  if  there  was  a sudden
ncrease  of  impedance  over  1500  ohms  for  the  pace/sense
ortion  of  the  lead  or  over  200  ohms  for  the  deﬁbrillation
ortions  of  the  lead  and/or  inappropriate  shock(s)  secondary
o  oversensing  of  electrical  noise  artefacts  on  electrogram
eview.  Functional  abnormalities  and  physiological  oversens-
ng  without  lead  electrical  dysfunction  were  not  considered
s  failures.  No  header  connector  problems  were  identiﬁed
t  surgical  exploration  for  lead  revision.
tatistical analyses
ontinuous  variables  were  expressed  as  mean  ±  standard
eviation  (SD)  or  median  (interquartile  range)  and  were
ompared  using  t  tests  for  independent  samples.  Differences
n  proportions  were  compared  using  the  Chi2 test.
We  used  the  Kaplan-Meier  method  to  estimate  lead  sur-
ivals.  Differences  between  survival  curves  were  analysed
sing  the  log  rank  test.  Leads  were  censored  if  patients  died,
ad  a  cardiac  transplantation  or  had  a  lead  removal  with-
ut  dysfunction  (endocarditis,  etc.).  Eventually,  leads  were
ensored  at  the  last  available  ICD  follow-up.  HRs  and  their
5%  CI  were  estimated  using  a  Cox  model.  The  proportional
azards  hypothesis  was  tested  by  assessing  the  statistical
igniﬁcance  of  time  by  covariate  interaction.
Statistical  analyses  were  performed  using  SPSS  15  soft-
are  (SPSS  Inc,  Chicago,  IL,  USA).  A  p  value  < 0.05  was
onsidered  statistically  signiﬁcant.N.  Girerd  et  al.
esultsData are mean (standard deviation) or percentage, unless
otherwise indicated.
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lFigure 1. Sprint Fidelis lead survival in the whole cohort (Panel 
years; Panel B).
During  a  median  follow-up  period  of  2.80  years
(interquartile  range  2.29;  mean  2.49;  range  0.01—5.32),
we  observed  33  Sprint  Fidelis  lead  failures  (12.3%)  result-
ing  in  3-year  and  5-year  survival  rates  of  87.4%  ±  2.6%  and
65.6%  ±  7.5%,  respectively  (Fig.  1,  Panel  A).  We  also  iden-
tiﬁed  37  deaths,  18  cardiac  transplantations  and  13  Sprint
Fidelis  lead  removals  without  signs  of  lead  dysfunction  (four
lead  dislodgments,  six  infections,  two  prophylactic  replace-
ments  and  one  suspected  dysfunction,  which  was  ruled  out
after  product  analysis).  No  deaths  related  to  lead  dysfunc-
tion  were  identiﬁed.
Table  2  reports  the  clinical  presentation  of  patients  with
Sprint  Fidelis  lead  failure.  Seventeen  patients  had  inappro-
priate  ICD  shocks,  with  one  patient  receiving  36  shocks.
However,  out  of  the  last  10  patients  with  lead  dysfunction,
only  two  experienced  inappropriate  ICD  shocks.
Predictors of Sprint Fidelis lead fracture
Age  was  a  signiﬁcant  predictor  of  lead  failure  in  the  univari-
ate  analysis  (HR  for  a  1-year  increase  0.97;  CI  0.95—0.99;
p  =  0.009;  Table  3).  None  of  the  other  demographic  or
implant  technique-related  factors  were  signiﬁcantly  asso-
ciated  with  risk  of  lead  failure  (all  p  >  0.10).  Of  note,
subclavian  venous  access  and  left  ventricular  ejection
y
y
t
fd in subsets of patients divided according to age (< 62.5 or > 62.5
raction  were  not  signiﬁcant  predictors  of  lead  failure
p  =  0.83  and  p  =  0.27,  respectively).
We  then  divided  our  population  into  two  age  groups
ccording  to  the  median  age  of  62.5  years.  Survival  with-
ut  Sprint  Fidelis  lead  failure  was  55.6%  ±  10.4%  in  patients
ged  <  62.5  years  (24/134  leads)  vs  78.6%  ±  8.8%  in  patients
ged  >  62.5  years  (9/135  leads)  (Fig.  1,  Panel  B).  Patients
ged  <  62.5  years  had  an  increase  in  the  risk  of  Sprint  Fidelis
ead  dysfunction  of  180%  (HR  2.80;  CI  1.30—6.02;  p  =  0.009;
able  3).
As  none  of  the  variables  tested  (other  than  age)  was  asso-
iated  with  lead  failure  with  p  values  <  0.10,  multivariable
nalysis  was  not  performed.
isk of lead failure over time
n  the  subgroup  of  patients  aged  <  62.5  years,  the  annual
ncidence  of  lead  dysfunction  increased  over  time  (Fig.  2).
ead  failure  annual  incidences  were  as  high  as  11.6%  ±  4.9%
uring  the  fourth  year  after  implantation  and  22.9%  ±  13.2%
uring  the  ﬁfth  year.  In  contrast,  the  annual  incidence  of
ead  dysfunction  was  less  than  5%  in  patients  aged  >  62.5
ears,  except  for  the  ﬁfth  year  (0.9%  ±  0.1%  for  the  ﬁrst
ear;  2.1%  [1.4%]  for  the  second  year;  4.0%  ±  2.3%  for  the
hird  year;  2.1%  ±  2.1%  for  the  fourth  year;  and  13.8%  ±  9.1%
or  the  ﬁfth  year).
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Table  2  Case  descriptions  of  fractured  Sprint  Fidelis  leads.
Patient  Time  since
implantation  at  lead
fracture
Number  of
inappropriate  shocks
due  to  lead  failure
Oversensing  Impaired
detection
threshold
High
pacing
impedance
Lead
extraction
1 1.65  16  Yes  Yes  No  Yes
2  1.28  2  Yes  No  No  No
3 3.56  N/A  Yes  Yes  Yes  Yes
4 0.94  36 Yes No  Yes  No
5 3.29  14 Yes No Yes  Yes
6 2.72  N/A Yes No No No
7  1.32  1  Yes  Yes  No  Yes
8  4.12  4  Yes  Yes  No  Yes
9  0.85  N/A  Yes  Yes  Yes  Yes
10  2.34  27  Yes  No  No  No
11  2.98  2  Yes  No  No  No
12  3.26  9  Yes  No  No  No
13  2.40  15  Yes  No  Yes  Yes
14  3.49  7  Yes  Yes  No  Yes
15  3.51  N/A  No  No  Yes  Yes
16  1.50  N/A  No  Yes  Yes  Yes
17  2.53  N/A  Yes  Yes  No  Yes
18  1.20  6  Yes  Yes  No  No
19  2.27  30  Yes  No  Yes  No
20  2.99  23  Yes  No  No  No
21  4.69  6  Yes  No  No  Yes
22  1.74  N/A  Yes  No  No  No
23  1.46  N/A  Yes  No  Yes  No
24  3.28  6  Yes  No  Yes  No
25  0.90  N/A  Yes  No  Yes  No
26  2.34  N/A  No  No  Yes  No
27  2.35  N/A  Yes  Yes  No  No
28  2.37  N/A  Yes  No  Yes  No
29 4.15  22  Yes  No  No  Yes
30  2.24  N/A  Yes  No  No  Yes
31 4.31  N/A  No  No  No  No
32 1.99  N/A  Yes  No  Yes  No
33 4.46  N/A Yes  No  Yes  No
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iscussion
mportant  ﬁndings  of  this  study  are  as  follows:  (1)  overall
ead  survival  at  5  years  in  our  large  single-centre  experience
as  less  than  70%;  (2)  younger  age  at  implantation  was  the
ain  predictor  of  Sprint  Fidelis  lead  failure;  (3)  the  annual
isk  of  lead  failure  in  patients  aged  <  62.5  years  was  higher
han  10%  during  the  fourth  and  ﬁfth  years  after  implanta-
ion.  There  are  signiﬁcant  practical  implications  of  these
esults  given  the  great  number  of  young  patients  implanted
ith  Sprint  Fidelis  leads  who  will  undergo  deﬁbrillator  gen-
rator  replacement  in  the  next  3  years.
There  is  great  controversy  concerning  the  frequency
f  Sprint  Fidelis  lead  dysfunction  [17—20]. To  the  best  of
ur  knowledge,  we  report  the  highest  rate  of  lead  fail-
re  (33/269  leads  [12.3%]).  This  high  prevalence  of  lead
ailure  is  probably  partly  explained  by  a  longer  follow-up
han  most  previously  published  papers  [17,20,21]. The  3-
ear  lead  survival  identiﬁed  in  our  population  (87.4%  ±  2.6%)
i
y
o
ts  in  line  with  the  results  published  in  previous  reports.
ndeed,  Faulknier  et  al.  and  Hauser  and  al.  reported  3-year
ead  survivals  of  90.8  and  87.9%,  respectively  [18,19].  Mor-
ison  et  al.  reported  a  30-month  lead  survival  of  89.3%  [15].
ue  to  the  longer  follow-up  in  the  current  study,  we  were
ble  to  estimate  5-year  lead  survival,  which  is  unfortunately
ramatically  low  (65.6%  ±  7.5%).  The  very  low  lead  survival
fter  3  years  of  lead  implantation  is  probably  explained  by  a
onlinear  increase  in  the  risk  of  lead  failure  over  time.  Two
ndependent  reports  showed  that  the  risk  of  Sprint  Fidelis
ead  failure  is  time  dependent  [17,19],  with  a  possible  expo-
ential  increase  as  time  from  implantation  increases  [17].
hese  results  raise  serious  concerns  regarding  the  annual
ate  of  Sprint  Fidelis  lead  failure  in  the  next  2  years.
This  study  also  revealed  that  younger  age  at  the  time  of
mplantation  is  a  strong  predictor  of  lead  failure.  Age  <  62.5
ears  at  implantation  was  associated  with  an  increased  risk
f  lead  failure  of  more  than  180%.  This  result  is  in  line  with
he  study  of  Morrison  et  al.,  which  reported  a  mean  age  of
Age  and  Sprint  Fidelis  lead  failure  393
Table  3  Risk  factors  for  Sprint  Fidelis  lead  dysfunction.
HR  CI  p
Age
For  a  1-year  increase  in  age  0.97  0.95—0.99  0.009
<  62.5  years  vs  >  62.5  years  2.80  1.30—6.02  0.009
Female  gender  1.18  0.49—2.88  0.709
Underlying  cardiomyopathy
Non-ischaemic  heart  failure Reference N/A N/A
Ischaemic  heart  failure 0.68 0.31—1.48  0.331
Others 2.08 0.81—5.30  0.127
Left  ventricular  ejection  fraction
For  a  10%  increase  in  ejection  fraction  1.15  0.90—1.49  0.270
<  30%  vs  ≥  30% 0.89  0.43—1.86  0.761
Implanted  ICD  systems
Single-chamber  device Reference N/A  N/A
Dual-chamber  device 1.01 0.28—3.62  0.991
Biventricular  device 2.63 0.34—20.7  0.358
Triple-chamber  device 0.72 0.28—2.38  0.716
Lead  model
6949  vs  6931  1.01  0.44—2.35  0.977
Implantation  technique
Right  device  side  vs  left  device  side 1.32 0.31—5.59  0.709
Subclavian  access  vs  cephalic  access 1.08 0.53—2.23  0.831
Apex  position  vs  septal  position  0.98  0.45—2.17  0.968
Lead  variables  at  implantation
Impedance  (for  a  10  ohm  increase)  1.00  0.98—1.02  0.954
Detection  threshold  (for  a  1  mV  increase)  0.97  0.92—1.04  0.392
Pacing  threshold  (for  a  1  V  increase)  1.62  0.67—3.92  0.281
CI: 95% conﬁdence interval; HR: hazard ratio; ICD: implantable cardioverter deﬁbrillator; NA: not applicable.
a49.5  years  in  patients  with  Sprint  Fidelis  lead  failure  vs  64.6
years  in  patients  without  Sprint  Fidelis  lead  failure  [15]. A
large  cohort  of  patients  recently  published  by  Hauser  et  al.
also  found  that  younger  age  was  signiﬁcantly  associated  with
Figure 2. Annual incidence of lead failure (one minus survival) in
patients aged less than 62.5 years.
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ﬁ higher  risk  of  Sprint  Fidelis  lead  failure  (HR  for  a  1-year
ncrease  was  0.98  vs  0.97  in  our  study)  [14]. This  ﬁnding
oncurs  with  most  previously  published  reports,  even  if  this
isk  was  not  directly  addressed  or  statistically  signiﬁcant
13,15—18].  It  is  also  consistent  with  the  higher  risk  of  lead
ysfunction  in  paediatric  patients  [22]. Higher  mechanical
train  due  to  greater  physical  activity  in  younger  patients
ight  explain  this  increased  risk.  Indeed,  a  higher  mean
uration  of  physical  activity  is  reportedly  associated  with
reater  risk  of  lead  failure  [17]. Interestingly,  Sprint  Fidelis
ead  failure  has  also  been  reported  to  occur  more  often  at
he  time  of,  or  closely  following,  physical  activity,  either
port  or  labour  [15]. These  activities  might  be  associated
ith  a  higher  mechanical  strain,  ultimately  promoting  lead
racture.  Of  note,  it  is  hypothesized  that  the  higher  rate  of
ead  dysfunction  in  young  patients  might  be  due  to  higher
jection  fraction  [15]. In  our  study,  lead  failure  was  not  asso-
iated  with  left  ventricular  ejection  fraction.  In  any  case,
echanistic  rather  than  epidemiological  studies  are  needed
o  draw  deﬁnitive  conclusions.
We  found  that,  in  patients  aged  <  62.5  years,  the  annualate  of  Sprint  Fidelis  lead  failure  was  greater  than  10%  during
he  fourth  year  after  implantation  and  over  20%  during  the
fth  year  after  implantation.  An  annual  failure  rate  above
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0%  at  the  fourth  year  has  been  recently  reported  by  others
18]. In  our  opinion,  these  results  suggest  that  virtually  all
print  Fidelis  lead  will  experience  failure  in  the  next  few
ears,  at  least  in  young  patients.  This  is  of  great  impor-
ance,  considering  that  most  of  these  patients  will  have
eﬁbrillator  generator  replacement  due  to  depleted  bat-
ery  in  the  next  2  years.  As  the  mean  longevity  of  ICD  is
pproximately  50  months  [23], replacement  of  deﬁbrillator
enerators  implanted  with  Sprint  Fidelis  leads  between  2004
nd  2007  is  expected  to  happen,  in  large  part,  before  the  end
f  2013.  Of  note,  only  33  of  our  patients  with  Sprint  Fidelis
eads  had  undergone  deﬁbrillator  generator  replacement  so
ar.
Our  results  suggest  that  it  might  be  reasonable  to  con-
ider  prophylactic  implantation  of  a  replacement  ICD  lead
ith  or  without  removal  of  the  Sprint  Fidelis  lead  at  the
ime  of  generator  replacement,  at  least  in  young  patients.
ndeed,  with  an  annual  rate  of  lead  failure  greater  than  10%,
 years  after  primary  implantation,  the  probability  of  a  nec-
ssary  redo  procedure  just  a  few  months  after  generator
eplacement  appears  to  be  very  high.  Moreover,  each  addi-
ional  procedure  on  the  pocket  is  associated  with  a  150%
ncrease  in  the  risk  of  complication  at  the  time  of  lead  revi-
ion  (multivariable  odds  ratio,  2.53;  p  =  0.02)  [11]. Revision
f  the  Sprint  Fidelis  lead  soon  after  generator  replacement
hould  consequently  be  considered  a  high-risk  procedure.
n  our  opinion,  considering  our  results  and  the  results  of
reviously  published  studies,  the  risk-beneﬁt  ratio  might
avour  implantation  of  a  new  ICD  lead  in  young  patients  — for
xample,  all  those  aged  <  60  years  at  the  time  of  generator
eplacement.  Ideally,  these  ﬁndings  should  be  conﬁrmed  by
uture  studies.  However,  time  is  of  the  essence  in  this  issue.
iven  the  time  needed  to  perform  a  study  and  publish  results
n  the  medical  science  literature,  most  relevant  deﬁbrilla-
or  generators  will  already  have  been  replaced  at  the  time
f  publication  of  conﬁrmative  studies.  From  our  point  of
iew,  there  are  sufﬁcient  data  supporting  an  increased  risk
f  lead  failure  in  young  patients  for  the  role  of  prophylac-
ic  lead  replacement  at  the  time  of  generator  replacement
o  be  systematically  discussed.  Whether  Sprint  Fidelis  leads
hould  be  explanted  or  abandoned  has  to  be  determined
y  other  studies.  In  a  large  study  that  included  more  than
50  patients  with  Sprint  Fidelis  lead  revisions,  the  risk  of
omplications  was  reported  to  be  greater  in  patients  with
ead  removal  (19.8%)  at  the  time  of  revision  than  in  those
hose  leads  were  abandoned  (8.6%)  [24]. Consequently,  the
anagement  of  Sprint  Fidelis  lead  revision  should  be  dis-
ussed  as  a  team,  especially  in  the  context  of  lead  revision
ithout  lead  abnormality.
In  any  case,  as  the  risk  of  lead  failure  is  very  high  in
ll  patients  implanted  with  Sprint  Fidelis  leads  compared
ith  others,  close  follow-up  is  warranted.  Remote  moni-
oring  is  associated  with  early  and  reliable  detection  of
CD  lead  failure  [25]. As  impedance  evolution  measured
uring  routine  clinic  monitoring  has  been  shown  to  be  unre-
ated  to  lead  failure  occurrence  [21], remote  monitoring
an  appropriately  be  the  cornerstone  of  follow-up.  Indeed,
s  the  recommended  3-month  follow-up  is  often  difﬁcult
o  achieve,  remote  monitoring  is  particularly  useful  in  the
atients  with  Sprint  Fidelis  leads.  In  addition,  the  Medtronic
ead  integrity  alert  algorithm  must  be  used  whenever  possi-
le  [26]. The  alert  algorithm,  which  can  be  downloaded  intoN.  Girerd  et  al.
reviously  implanted  ICDs,  is  triggered  by  either  oversensing
r  high  lead  impedance.  If  triggered,  the  algorithm  increases
he  number  of  intervals  to  detect  ventricular  ﬁbrillation  in
rder  to  avoid  inappropriate  shocks.  It  should  be  stressed
hat  the  lead  integrity  alert  algorithm  has  been  shown  to
igniﬁcantly  decrease  the  risk  of  inappropriate  shocks  in
he  setting  of  lead  failure  [27]  and  that  its  use  is  recom-
ended  by  the  Heart  Rhythm  Society  Task  Force  on  Lead
erformance  [28]. These  tools,  mainly  the  Medtronic  lead
ntegrity  alert  algorithm,  are  used  in  the  majority  of  our
atients,  which  could  explain  the  decrease  in  inappropriate
hocks  observed  over  time  in  our  population.
imitations
ur  results  are  subject  to  the  usual  limitations  of  a  ret-
ospective  study.  Some  interesting  medical  information
as  not  available  (physical  activity,  sport  practice,  radio-
raphic  measurements  of  lead  angles,  etc.).  Moreover,  most
ead  failures  were  not  returned  for  product  analyses.  The
ause/type  of  lead  dysfunction  was  consequently  not  sys-
ematically  veriﬁed.
This  was  a  single-centre  study.  It  is  difﬁcult  to  derive
anagement  guidelines  from  our  limited  sample  of  patients.
owever,  our  results  are  highly  consistent  with  previous
eports,  especially  regarding  the  high  rate  of  lead  failure
n  young  patients  [14,15,18].
onclusions
print  Fidelis  lead  failure  is  much  more  frequent  in  younger
atients,  rising  to  as  high  a rate  as  22%  per  year  during  the
fth  year  after  implantation.  This  result  might  encourage
he  prophylactic  implantation  of  a  new  ICD  lead  at  the  time
f  generator  replacement.
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